For research use only. Not for therapeutic Use.
VPC-14228 is a potent androgen receptor DNA binding domain (AR-DBD) inhibitor that interferes with the interaction of AR with androgen response elements and effectively blocks AR transcriptional activity. VPC-14228 can be used in prostate cancer research[1].
| Catalog Number | I012135 |
| CAS Number | 19983-28-9 |
| Synonyms | 4-(4-phenyl-1,3-thiazol-2-yl)morpholine |
| Molecular Formula | C13H14N2OS |
| Purity | ≥95% |
| InChI | InChI=1S/C13H14N2OS/c1-2-4-11(5-3-1)12-10-17-13(14-12)15-6-8-16-9-7-15/h1-5,10H,6-9H2 |
| InChIKey | MRNNJVNMXOZEQC-UHFFFAOYSA-N |
| SMILES | C1COCCN1C2=NC(=CS2)C3=CC=CC=C3 |
| Reference | [1]. Kush Dalal, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289(38):26417-26429. |
